Brief: Allergy Therapeutics Says Further Advancement Via Patient Cohorts In Phase I/IIa VLP Peanut PROTECT Trial
17/09/2024 07:48
Sept 17 (Reuters) - Allergy Therapeutics PLC AGY.L :
* ALLERGY THERAPEUTICS PLC: FURTHER ADVANCEMENT THROUGH
PATIENT
COHORTS IN PHASE I/IIA VLP PEANUT PROTECT TRIAL
* ALLERGY THERAPEUTICS: NO RELEVANT SAFETY OR TOLERABILITY
FINDINGS OBSERVED IN EITHER PEANUT ALLERGIC PATIENTS OR HEALTHY
SUBJECTS AT HIGHER DOSES
Source text for Eikon: ID:nRSQ3864Ea
Further company coverage: AGY.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allergy Therapeutics
See all newsBrief: Allergy Therapeutics Expects FY 2026 Revenue Of £59.90 Million, Up 9% Reported
UK's Allergy Therapeutics FY revenue beats on Grassmuno launch
Allergy Therapeutics - Trading update for the year ended 30 June 2026
Brief: Allergy Therapeutics Appoints Helge Weiner-Trapness As Executive Chairman
Allergy Therapeutics - Appointment of Executive Chairman